GUARDANT HEALTH, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.65 USD | +2.71% |
|
+31.14% | -8.76% |
| Sales 2024 * | 680M 53.99B | Sales 2025 * | 810M 64.38B | Capitalization | 2.94B 233B |
|---|---|---|---|---|---|
| Net income 2024 * | -385M -30.58B | Net income 2025 * | -342M -27.17B | EV / Sales 2024 * | 4.69 x |
| Net Debt 2024 * | 253M 20.07B | Net Debt 2025 * | 481M 38.18B | EV / Sales 2025 * | 4.22 x |
| P/E ratio 2024 * |
-7.53
x | P/E ratio 2025 * |
-8.41
x | Employees | 1,774 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Guardant Health, Inc.
More recommendations
More press releases
More news
| 1 day | +2.77% | ||
| 1 week | +31.14% | ||
| Current month | +37.11% | ||
| 1 month | +44.67% | ||
| 3 months | +11.93% | ||
| 6 months | +0.78% | ||
| Current year | -8.76% |
1 week
18.01
25.85
1 month
15.8125.85
Current year
15.8127.61
1 year
15.8141.06
3 years
15.81133.82
5 years
15.81181.07
10 years
15.81181.07
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Wiley
FOU | Founder | 48 | 31/12/11 |
AmirAli Talasaz
FOU | Founder | 44 | 31/12/11 |
Helmy Eltoukhy
CEO | Chief Executive Officer | 45 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Clark
BRD | Director/Board Member | 62 | 30/11/16 |
Myrtle Potter
BRD | Director/Board Member | 65 | 14/10/21 |
Vijaya Gadde
BRD | Director/Board Member | 49 | 31/05/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.22% | 0 M€ | 0.00% | - | |
| 0.64% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 24.7 | +2.92% | 2 867 493 |
| 13/05/24 | 24 | +7.29% | 4,186,227 |
| 10/05/24 | 22.37 | +15.07% | 5,869,005 |
| 09/05/24 | 19.44 | +4.29% | 2,817,517 |
| 08/05/24 | 18.64 | -0.96% | 1,623,524 |
Delayed Quote Nasdaq, May 14, 2024 at 08:07 pm
More quotes
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Calendar
15/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
24
USD
Average target price
37.39
USD
Spread / Average Target
+55.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.76% | 2.94B | |
| -29.22% | 10.26B | |
| +32.84% | 3.04B | |
| -13.62% | 2.19B | |
| -16.78% | 1.72B | |
| +64.12% | 1.4B | |
| +28.58% | 780M | |
| -2.18% | 736M | |
| -18.57% | 560M | |
| +3.18% | 293M |
- Stock Market
- Equities
- GH Stock
